Biotechnology is rapidly becoming a strategic pillar of economic competitiveness, public health resilience, and national security. From genomics and cell therapies to diagnostics and bio-manufacturing, breakthroughs in life sciences are reshaping medicine — yet the path from discovery to impact is long, capital-intensive, and uncertain. Governments increasingly want to support biotech ecosystems, but often struggle to design policies and investment strategies aligned with how science and capital actually work. This session examines what governments should learn from the biotech investment landscape. Bringing together perspectives from investment banking, frontier research, and venture capital, the discussion will explore how biotech innovation is funded, where public policy can accelerate or hinder progress, and how governments can act as effective enablers rather than distorting forces. The conversation will focus on aligning public ambition with scientific reality — ensuring long-term value creation, resilience, and societal benefit.